<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Twenty eight patients of <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) were treated with low dose <z:chebi fb="1" ids="16040">cytosine</z:chebi> <z:chebi fb="0" ids="22601">arabinoside</z:chebi> to study the effect of this treatment modality </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients presented with a <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> of less than 12 Gm/dl, 4 (15%) had <z:hpo ids='HP_0001875'>neutropenia</z:hpo> with an absolute neutrophil count of less than 500 x 10(6)/L and 18 (65%) had <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> of less than 100 x 10(9)/L </plain></SENT>
<SENT sid="2" pm="."><plain>The subtypes according to the bone marrow evaluation included 14 patients of <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess blasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>), 10 <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess blasts in transformation (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB-T</z:e>), and 4 <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>) </plain></SENT>
<SENT sid="3" pm="."><plain>Five patients (18%) achieved complete hematological response, 10 (36%) had a partial response and 9 (33%) patients had no response </plain></SENT>
<SENT sid="4" pm="."><plain>Four patients died early during treatment due to <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> lysis (1 CMML) and <z:mp ids='MP_0001914'>hemorrhage</z:mp> (3 RAEB) </plain></SENT>
<SENT sid="5" pm="."><plain>Seven patients progressed to <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) while on therapy and three progressed to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> after completion of therapy </plain></SENT>
<SENT sid="6" pm="."><plain>Five patients died of <z:mp ids='MP_0001914'>hemorrhage</z:mp> and 3 of <z:e sem="disease" ids="C0036690" disease_type="Disease or Syndrome" abbrv="">septicaemia</z:e> after achieving an objective response </plain></SENT>
<SENT sid="7" pm="."><plain>The mean duration of follow up in these patient was 8 months (range 1 month-3 years) </plain></SENT>
<SENT sid="8" pm="."><plain>Only 3 patients of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> have survived for greater than 2 years </plain></SENT>
<SENT sid="9" pm="."><plain>Our data reveals the short term benefit of this mode of therapy and emphasizes the need to develop newer therapeutic approaches </plain></SENT>
</text></document>